Signal Transduction and Targeted Therapy

Article	Citations
Greasy hair against obesity	1995
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	1753
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1642
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1337
Moving towards precision psychiatry: the hard nut of depression	1228
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1208
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	1067
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	1004
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	982
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	961
Identification of glutamine as a potential therapeutic target in dry eye disease	946
Correction: The Hippo signalling pathway and its implications in human health and diseases	879
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	874
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	869
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	834
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	817
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	781
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	780
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	769
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	769
Dopamine as a teaching signal: understanding its role in shaping individual behavior	764
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	763
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	756
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT	749
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	735

PD-1 and LAG-3: synergistic fostering of T cell exhaustion	735
Correction: Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine	718
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	693
Sensory neurons: unveiling the symphony of wound healing	652
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	622
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	602
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	599
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry	594
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	590
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	570
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	570
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance	570
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	561
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	549
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	540
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	539
Animal models for COVID-19: advances, gaps and perspectives	534
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	530
Neutrophil extracellular traps in homeostasis and disease	529
Phototherapy in cancer treatment: strategies and challenges	518
Signal pathways of melanoma and targeted therapy	514
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination	511
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	510
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	502
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	488
Top(ological-operon) secret behind the long-range transcriptional coupling	487
Omicron spike protein: a clue for viral entry and immune evasion	478
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	476
Beyond borders: the choroid plexus-immune communication during neuroinflammation	470
PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron	454
Platelets and diseases: signal transduction and advances in targeted therapy	451
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	450
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	448
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	447
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	438
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	437
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	429
Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant	427
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	417
Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver	416
The RING finger protein family in health and disease	413
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	395
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	384
Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis	382
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	380
Harnessing innate immune pathways for therapeutic advancement in cancer	365
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	361
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	358
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	356
Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair	356

Microbiota in health and diseases	351
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	347
Mind-body control: a new perspective on motor neuron function	344
Base editing: a promising tool to rescue spinal muscular atrophy	340
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	334
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	329
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	323
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	323
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	316
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	313
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	312
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	310
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	303
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	302
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	297
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	294
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	293
sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster	292
Nascent mRNA damage: depot and disposal	285
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	284
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	275
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	275
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	275
Persistent SARS-CoV-2 infection in asymptomatic young adults	275
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	272
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	272
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	271
Mitochondrial heterogeneity in diseases	269
Molecular insights of exercise therapy in disease prevention and treatment	268
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	268
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	266
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies	266
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	260
Small molecules in the treatment of COVID-19	252
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	251
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	248
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	247
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	246
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	245
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	240
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	238
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	235
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	235
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	233
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	233
Targeting PI3K/Akt signal transduction for cancer therapy	233
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	231
Lactate metabolism in human health and disease	228
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	225
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	221
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	220
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	219
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	219
Single-cell genomics: the human biomolecular and cell atlases	214
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	213
Back to pluripotency: fully chemically induced reboot of human somatic cells	211
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	210
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	209
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	207
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	206
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	206
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	205
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	205
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	205
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	204
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	203
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	201
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	199
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	198
Programmable synthetic receptors: the next-generation of cell and gene therapies	198
Current landscape of innovative drug development and regulatory support in China	196
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	196
Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study	196
Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice	194
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	194
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	190
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants	190
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	190
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	189
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer	188

mRNA-based therapeutics: powerful and versatile tools to combat diseases	181
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	180
Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer	180
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	179
Signaling pathways and targeted therapies for psoriasis	175
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	174
Activated STING: an ion channel to trigger non-interferon-related functions	173
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	173
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing	173
Time’s up: mutation rate and lifespan	171
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	167
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	167
Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution	167
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	167
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	161
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	161
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	160
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	159
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	158
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	157
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape	157
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	156
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	156
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	154
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	152
Targeted protein degradation: advances in drug discovery and clinical practice	151
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	149
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	148
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	148
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	146
Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages	146
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	140
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	139
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	139
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	138
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates	135
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	134
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	133
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	132
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	132
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	132
Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone	131
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	131
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	130
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	130
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	130
Artificial intelligence in cancer target identification and drug discovery	129
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	127
Signaling pathways in obesity: mechanisms and therapeutic interventions	127
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	126
Redox regulation: mechanisms, biology and therapeutic targets in diseases	126
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	126
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	125
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	123
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern	122
SLC7A11: a new regulator in diabetic wound healing	122
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	121
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	121
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation	121
NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity	121
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	120
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	119
Intratumoural microbiota: a new frontier in cancer development and therapy	118
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications	117
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	117
CAR-T cell therapy for cancer: current challenges and future directions	117
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches	115
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)	115
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing	115
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal c	114
The gasdermin family: emerging therapeutic targets in diseases	114
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	114
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	114
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy	112
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	111
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	111
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	110
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	109
A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment	108
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial	107
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	107
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	107
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	107
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	106
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	105
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	105
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	105
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	104
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	103
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	101
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	101
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure	100
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	98
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	97
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	97